Skip to main content
FHTX
NASDAQ Life Sciences

Foghorn Swings to $58.2M Q3 Net Income, Extends Cash Runway to 2H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.87
Mkt Cap
$111.051M
52W Low
$1.79
52W High
$7.61
52W Position info
4.5% above low
Off High info
75% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

FHTX is trading near its 52-week low of $1.79 (4.5% above the low).

Summary

Foghorn reported Q3 2026 net income of $58.2M, almost entirely from a $74.1M catch-up adjustment after dropping the Lilly-partnered programs, and said $156.2M in cash funds operations into the second half of 2029. The pipeline is now wholly owned but early — first-in-human for the IBD program is targeted by end of 2027.


Key Events · Earnings and Guidance · FHTX

  • Q3 Swing to Net Income on Catch-Up Adjustment

    Net income was $58.2M versus a $15.8M net loss a year earlier, driven by collaboration revenue of $83.5M that included a $74.1M cumulative catch-up adjustment tied to the decision not to advance FHD-909 and the SMARCA2 selective degrader.

  • Cash Runway Extended to Second Half 2029

    Cash, cash equivalents and marketable securities totaled $156.2M at September 30, 2026, funding operations into the second half of 2029 versus the mid-2027 runway in the prior baseline.

  • Restructuring Costs Booked in the Quarter

    The quarter included $2.3M of restructuring costs, reflecting the 40% workforce reduction disclosed on October 1, 2026 alongside the Lilly program discontinuation.

  • Wholly Owned Pipeline With 2027 Milestones

    The IBD oral small molecule begins dose-range finding in Q4 2026 with first-in-human targeted by end of 2027; the selective EP300 degrader has an IND targeted in 2027 focused on multiple myeloma and DLBCL.


Analysis · FHTX · Life Sciences

The headline profit is an accounting event, not an operating one: $83.5M of collaboration revenue includes a $74.1M cumulative catch-up adjustment triggered by formally abandoning the Lilly-partnered FHD-909 and SMARCA2 programs. What actually changes the thesis is the balance sheet. With $156.2M of cash and runway now into the second half of 2029 — roughly two years beyond the mid-2027 runway in the prior baseline — the company has bought time to advance wholly owned programs. Those programs remain early: the IBD small molecule targets first-in-human by end of 2027 and the EP300 degrader targets an IND in 2027, so there is no near-term clinical readout to reprice the stock. With shares near the 52-week low of $1.79, the market is valuing the platform at a steep discount to cash plus deferred revenue; today's filing does not add a catalyst, it removes a financing overhang.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FHTX was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.1M. The 52-week trading range was $1.79 to $7.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FHTX - Latest Insights

FHTX
Nov 09, 2026, 7:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.87
Real-time Price: $1.87 info
Change: $0 (0%) info
Market Cap: $111.051M info
FHTX
Oct 01, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.57
Real-time Price: $1.87 info
Change: -$1.70 (-48%) info
Market Cap: $111.051M info
FHTX
Oct 01, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.57
Real-time Price: $1.87 info
Change: -$1.70 (-48%) info
Market Cap: $111.051M info
FHTX
May 07, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $1.87 info
Change: -$2.81 (-60%) info
Market Cap: $111.051M info
FHTX
May 07, 2026, 7:02 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $1.87 info
Change: -$2.81 (-60%) info
Market Cap: $111.051M info